Prelude Therapeutics Incorporated : April 2022 Corporate Presentation

Precision Oncology Redefined

April 2022

Forward-Looking Statements

This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commercialize small molecule therapies, our expectations about timing and ability to commence, enroll or complete clinical studies and to obtain regulatory approvals for PRT543, PRT811, PRT1419, PRT2527 and other candidates in development, the ability of our product candidates to treat various cancers, the ability to discover additional suitable candidates for regulatory approval, the potential impact of the COVID-19 pandemic and the sufficiency of our cash and cash equivalents to fund our operations.

Any statements contained herein or provided orally that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by such terminology as ''believe,'' ''may,'' ''will,'' ''potentially,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''could,'' ''would,'' ''project,'' ''plan,'' ''expect'' and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. Statements, including forward-looking statements, speak only to the date they are provided (unless an earlier date is indicated).

These forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to us. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. If such assumptions do not fully materialize or prove incorrect, the events or circumstances referred to in the forward-looking statements may not occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Additional risks and uncertainties that could affect our business are included under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the three months ended September 30, 2021 and in our Annual Report on Form 10-K for the year ended December 31, 2021.

Prelude Therapeutics: Vision

Build a fully integrated oncology company on the

foundation of drug discovery excellence to deliver

novel precision cancer medicines to

underserved patients

Prelude Therapeutics: Key Reasons to InvestExperienced Management Team: Proven Track Records

Kris Vaddi, PhD

Founder & Chief Executive

Officer

Deborah Morosini, MD, MSW

Executive Vice President and Chief of Clinical Affairs

Jane Huang M.D.

President and Chief

Medical Officer

Andrew Combs, PhD

Executive Vice President and Head of Chemistry

Board of Directors

Paul Friedman, MD

CEO

Former CEO

Mardi Dier

CFO

Former CFO, CBO

Victor Sandor, MD

Former CMO

David Bonita, MD

General Partner

Julian C. Baker

Managing Member

Baker Brothers Investments

Kris Vaddi, PhD

Founder &

Chief Executive Officer

Martin Babler

Former CEO